



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, Mail Stop Amendment, P.O.
Box 1450, Alexandria, VA 22313 on June 24, 2005

By: Jill R. Clarke
Jill R. Clarke

PATENT
Attorney Docket No.: P0026US20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

John B. WELSH *et al.*

Application No.: 10/054,498

Filed: January 22, 2002

For: GENES OVEREXPRESSED IN
PROSTATE DISORDERS AS
DIAGNOSTIC AND THERAPEUTIC
TARGETS

Examiner: Susan Ungar, Ph.D.

Art Unit: 1642

Confirmation No.: 4754

**SUBMISSION OF SEQUENCE LISTING
UNDER 37 CFR 1.821-1.825**

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Arlington, VA 22313-1450

This is in response to the Notice to comply with sequence listing requirement mailed February 24, 2005 for the above-identified patent application. Applicants submit herewith a Sequence Listing in compliance with the requirements of 37 CFR 1.821-1.825. Enclosed are an initial computer readable form (CRF) copy of the Sequence Listing, a paper copy of a Sequence Listing (pages 1-190), and an amendment directing entry of the Sequence Listing into the above-identified patent application.

It is hereby stated that the content of the sequence listing information recorded in computer readable form is identical to the written paper copy of the sequence listing and introduces no new matter.

The Director is authorized to deduct any additional fees from, or credit any overpayment to, the undersigned's Deposit Account No. 50-1885.

Respectfully submitted,



Hugh Wang, Ph.D.
Reg. No. 47,163

Customer No.: 29490

GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION
10675 John Jay Hopkins Drive, Room E227
San Diego, CA 92121
Tel: (858) 812-1539
Fax: (858) 812-1981